Breast Cancer (BC) is among women’s most lethal health concerns. Early diagnosis can alleviate the mortality rate by helping patients make efficient treatment decisions. Human Epidermal Growth Factor Receptor (HER2) has become one the most lethal subtype of BC. According to the College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO), the severity level of HER2 expression can be classified between 0 and 3+ range. HER2 can be detected effectively from immunohistochemical (IHC) and, hematoxylin & eosin (HE) images of different classes such as 0, 1+, 2+, and 3+. An ensemble approach integrated with threshold filtered single instance evaluation (SIE) technique has been proposed ...
Evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) is subject ...
Generally, human epidermal growth factor 2 (HER2) breast cancer is more aggressive than other kinds ...
Human epidermal growth factor receptor 2 gene- (HER2-) targeted therapy for breast cancer relies pri...
Breast Cancer (BC) is among women's most lethal health concerns. Early diagnosis can alleviate the m...
Abstract Objective Breast cancer is a significant health issue for women, and human epidermal growth...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
Human epidermal growth factor receptor 2 (HER2) evaluation commonly requires immunohistochemistry (I...
Aims: Evaluating expression of the human epidermal growth factor receptor 2 (HER2) by visual examina...
Nuclei classification is a mandatory process to obtain scoring information for whole slide images (W...
Accurate detection of HER2 expression through immunohistochemistry (IHC) is of great clinical signif...
Background and Objective: Visual expression of invasive breast cancer with immunohistochemistry (IHC...
Classifying histopathology images on a pixel-level requires sets of features able to capture the com...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by ...
One of the major challenges in the development of early diagnosis to assess HER2 status is recognize...
Evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) is subject ...
Generally, human epidermal growth factor 2 (HER2) breast cancer is more aggressive than other kinds ...
Human epidermal growth factor receptor 2 gene- (HER2-) targeted therapy for breast cancer relies pri...
Breast Cancer (BC) is among women's most lethal health concerns. Early diagnosis can alleviate the m...
Abstract Objective Breast cancer is a significant health issue for women, and human epidermal growth...
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to det...
Human epidermal growth factor receptor 2 (HER2) evaluation commonly requires immunohistochemistry (I...
Aims: Evaluating expression of the human epidermal growth factor receptor 2 (HER2) by visual examina...
Nuclei classification is a mandatory process to obtain scoring information for whole slide images (W...
Accurate detection of HER2 expression through immunohistochemistry (IHC) is of great clinical signif...
Background and Objective: Visual expression of invasive breast cancer with immunohistochemistry (IHC...
Classifying histopathology images on a pixel-level requires sets of features able to capture the com...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by ...
One of the major challenges in the development of early diagnosis to assess HER2 status is recognize...
Evaluation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) is subject ...
Generally, human epidermal growth factor 2 (HER2) breast cancer is more aggressive than other kinds ...
Human epidermal growth factor receptor 2 gene- (HER2-) targeted therapy for breast cancer relies pri...